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A B ST R A C T
Angiogenesis is an established indispensable process in the developm ent and m etastasis o f solid tumors. Its 
significance in the pathogenesis and progression o f hem atological m alignancies is still to be elucidated. Data 
have recently been accum ulated about its role in chronic myeloid leukem ia (CM L). The aims o f our study 
were: (I) to assess vascular endothelial growth factor (VEG F) and hepatocyte growth factor (HGF) plasma 
levels in patients with newly diagnosed, untreated and treated CM L; (II) to analyze the differences of their 
levels in varying phases o f the disease; (III) to analyze VEGF and HGF correlation with some markers reflect­
ing the tumor burden as well as the progression o f the disease. Plasma levels o f  VEGF and HGF were deter­
mined by ELISA in 16 patients with CM L and in 21 healthy individuals. VEG F and HGF levels were 
followed-up in 6 patients according to the progression of the disease or the treatm ent regim en. All the patients 
with CML showed significantly higher levels o f VEG F and HGF when com pared to the control group. We 
found a significant correlation between HGF and leukocytes, LDH, splenom egaly and blast percentage in the 
peripheral blood. Significant correlation was found between VEGF and platelets, LDH and leukocytes. Our 
data indicate that CML are highly associated with elevated plasm a levels o f  VEG F and HGF, which corrobo­
rates the thesis o f its angiogenic dependency. Likewise, the present study suggests that m easurem ents of 
VEGF and HGF may be useful for assessing disease activity and progression as well.
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INTRO DUCTIO N
Angiogenesis is a process of forming a new blood network 
from a preexisting vasculature. It involves degradation of 
extracellular matrix proteins, activatioa proliferation and migra­
tion of endothelial cells and pericytes. Except its physiologic 
role in ovulation, placentation and embiyogenesis, angiogenesis 
is an integral step in the growth, dissemination and metastasis of 
solid tumors ( 1 ). Many positive and negative regulatory mole­
cules are involved in tire angiogenic process. The analysis of tire 
degree of intratumoral neovascularization as well as the expres­
sion of some proangiogenic factors may provide prognostic in- 
fonnauon in patients with certain solid tumors (2,3). Substantial 
research data Irave recently been accumulated about tire role of 
angiogenesis in hematological malignancies. Increased mi- 
cro-vessel density and high serum levels of proangiogenic fac­
tors liave been reported tn patients with myelodysplastic syn­
drome, (MDS). acute myeloid leukemias (AML), chronic
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lymphoproliferalive disorders (4), myeloproliferative disorders 
(MPD), (4,5,6) and. multiple myeloma (MM ) (7 ). Tire possible 
prognostic significance of increased angiogenesis lias so far 
been found in patients with MM that provides a rationale for 
clinical investigations of tire anti-angiogenic agent Thalidomide 
in this disease as a part o f tire salvage therapeutic regimens. 
During embryonic developmenl hematopoietic stem cells 
(HSCs) and early endothelial cells (EC) originate from a com- 
nxin precursor cell known as hemangioblast Given this com­
mon origin, it is suggested that HSCs has a significant role in 
angiogenesis during the embryogenesis (8). With fire identifica­
tion of the hemangioblast in adult individuals (9), we can specu­
late that the tight relatioaslrip between hematopoiesls and 
angiogenesis are preserved during foe postnatal life.
VEGF and HGF are among foe most specific and potent induc­
ers of angiogenesis. Their elevated plasmatic levels serve as in­
direct markers of increased angiogenic activity. VEGF is a 
multifunctional protein which activates its endothelial receptors 
and leads to an increased capillary permeability, endothelial cell 
proliferation and migration. The autocrine and paracrine actions 
of VEGF are studied in leukemias and MDS by some authors. 
Fiedler et al. ( 10) demonstrate that foe bone marrow endothe­
lium releases leukemic growth factors (GM-CSF, IL-6,
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Fas-Iigand) and, in tum, die leukemic cells secrete VEGF which 
means that VEGF receptors on leukemic cells are functional, 
and thus they initiate endothelial proliferation and expansion of 
the bone marrow capillary net The growing endothelial mass 
supports the leukemic progression in a paracrine manner with 
an increased production of growth factors (10). On the other 
liand, the expression of VEGF receptors by leukemic cells leads 
to an establishment of an autocrine loop and thus, supporting 
their migration and survival (10,11). HGF (also known as 
"scatter" factor) is produced by mesenchyme cells as well as by 
bone marrow stromal cells. It regulates the cell growth, motility 
and morphogenesis of various cell types. Its significance for the 
normal and malignant hematopoiesis has been determined 
(12,13). HGF induces proliferation and migration of FISCs in 
patients with AML and MDS in vitm, therefore it could contrib­
ute to the malignant potential o f these cells (13).
Since MPD, and particularly CML, serve as a model o f deregu­
lation ofHSCs that results in an excessive myeloid proliferation, 
it is reasonable to expect an increased angiogenesis in these dis­
orders as well. The data about the clinical significance of 
angiogenesis in CML are contradictory and insufficient For this 
reason we give our attention to investigate angiogenic activity in 
CML and other MPD. Some data published by now (4,5), as 
well as our own ( 14), noticed that tire levels o f VEGF and HGF 
are increased in patients with chronic MPD. In this article we 
analyze in detail tire differences in cytokine levels in various 
phases of CML, the correlation with some markets reflecting 
the tumor burden and progression o f the disease as well as the 
clinical significance o f VEGF and HGF.
M A T E R IA L  A N D  M E T H O D S
1. The study group is classified and presented on Table 1. 
The control group consists o f 21 volunteers with no clinical 
or laboratory signs o f malignancy or active disease.

















Age (years) 46(18-71) 40(23-66)
Male/female
ratio 10/6 8/13
2. Plasma samples. According to the published data, 15 there 
are differences between the plasma and serum concentra­
tions o f  VEGF which may be due to its release from the 
platelets during the process of blood-clotting. Following the 
recommendations o f working with plasma not with serum
probes, we fixed on methods as follows: the blood probes 
were collected through venepunction in EDTA anticoagu­
lant tubes in order to prevent the activation o f blood-clotting 
systems; so-processed materials were centrifuged immedi­
ately at 3000 tpm for 7-8 min and 1ml plasma samples were 
separated, frozen and stored at -32°C.
3. Cytokine levels. Using enzyme-linked immunosorbent as­
say (ELISA), the plasma levels o f VEGF and HGF were de­
termined according to the instructions o f  the given protocols: 
(Quantikine human VEGF and Quantikine human HGF 
ELISA kits, from R&D Systems, MN). Tire assay sensitiv­
ity for VEGF and HGF are 9pg/ml and 40pg/ml. respec­
tively.
4. Statistical analyses. We perfonned the analyses with SPSS 
10.0 statistical program for Windows. The following 
non-parametrical tests were used: Mann-Whitney U and 
Wilcoxon W tests (to analyze the cytokine differences 
among the study groups), and Spearman’s Rho test (to assess 
the correlations between cytokine levels and some markers 
reflecting the tumor burden and progression o f the disease),
R E SU L T S A N D  D ISC U SSIO N
1. Plasmatic concentrations o f  VEGF and HGF
1.1. Elevated plasmatic concentrations o f  VEGF and HGP 
in patients with CML in chronic, accelerated and blast cri­
sis phases o f  the disease. The summary o f the results is 
given in Table 2, Fig. 1 and Fig. 2.
Initially, we tested the differences in VEGF and HGF levels 
between all o f  the CML patients and the control group, 
VEGF and HGF levels were significantly higher in the 
plasma samples o f  CML group as compared with the con­
trol group (p<0,0001, Mann-Whitney U test). The median 
VEGF in plasma samples o f CML was 305pg/ml, and re­
spectively 45pg/ml in the control group. Higher levels ol 
HGF were found in CML patients with median level ol 
2563,5pg/ml than in the control group (744pg/ml). With re­
spect to these findings, threshold values were found foi 
both VEGF and HGF plasma levels between the 2 group 
(CML patients and controls). Additionally, we divided the 
CML plasma samples in accordance with the three phase 
o f the disease to test the differences among their cytokira 
levels. Intriguingly, we found no increase o f  VEGF plasnu 
levels during the progression from chronic CML to bias 
crisis (p<0,6, Mann-Whitney U, Wilcoxon W tests). Con 
versely, the increase o f  HGF plasma levels were of great 
significance and conespondence with the progression to 
blast transformation (p<0,001, Mann-Whitney II, 
Wilcoxon W tests).
1.2. Comparison o f  VEGF and H G F levels in untreatd 
and treated CML patients and controls.
We tested 22 plasma samples from CML patients accord 
mg to the treatment, as we divided die patients in treate 
and untreated groups. We made no difference among the 
various treatment regimens for the main goal o f the evalua­
tion was not to be analyzed the angiogenic properties of thf 
drugs but the activity o f  the disease.
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N Mean SD Min. Max.
Percentiles
25th 50th(Median) 75th
Control group 21 48 22,19 10 83 . 32 45 68
CML (all cases) pO.001 16 746 888,73 25 3064 172 305 1127
CML (Chronic phase) p<0.001 8 1012,25 1170,89 25 3064 172 367,5 2192,5
CML (Acceleration) p<0.01 3 427,66 351,52 180 830 180 273 830
CML (Blast crisis) p<0.001 5 513 464,01 116 1226 143 330 974,5
HGF pg/ml
Control group 21 749,9 244 270 1198 609,5 744 902
CML (all cases) pO.OOOl 16 5009,5 5565,69 601 18000 1103,5 2563,5 7818
CML (Chronic phase) p<0.01 8 2412,38 2366,89 601 6752 875,5 1184,5 4688,75
CML (Acceleration) p<0.01 3 2343 1080.44 1100 3057 1100 2872 3057













































N =  21 16 8 3 5
Controls CML chronic phase CML blast crisis 
CML CML acceleration
Fig. I. Comparison o f  VEGF levels in CML. different 
phases o f  CML and control group
As it is seen in Table 3, Fig. 3 and Fig. 4, the levels o f VEGF 
and HGF are significantly higher in untreated CML patients 
titan those treated with chemotherapy and the healthy individ­
uals from the control group. The median levels o f VEGF and 
HGF in treated patients were slightly higher titan those in the 
controls and there was no significant difference for HGF when 
we performed the statistical test
2. Correlation analyses between cytokine levels and some 
markers reflecting the tumor burden as well as the progres­
sion of CML. The results are presented on Table 4. 
According to our data the most significant correlation was 
found between HGF plasma levels and leukocytes (WBC),
N =  21 16 8 3 5
Controls CML chronic phase CML blast crisis 
CML CML acceleration
Fig. 2. Comparison o f  HGF levels in CML, different 
phases o f  CML and control group
blasts percentage in peripheral blood (PB), lactate dehyd­
rogenase enzyme activity (LDH) and splenomegaly. 
VEGF levels correlated mostly with WBC and LDH, mod­
erately with platelets but, in contrast to HGF, there was no 
correlation with blast cells in PB. Having in mind that the 
levels o f  VEGF do not increase significantly during the 
blast crisis in CML patients (Table 2 and Fig. 1), we can 
suspect that VEGF cannot predict the blast transformation 
o f  CML as contrasted with the higher HGF levels in this 
phase o f the disease.
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N Mean SD Min Max
Percentiles
(controls) 75th
Controls * 21 48 22,19 10 83 32 45 68
Treated p<0.03 8 108,5 81,28 25 278 44 92 144,75
Untreated pO.0001 14 841 913227 116 3064 230,25 : 392,5 1278,25
HGF pg/ml
Controls ♦ 21 749,9 244 270,00 1198 609.5 1 744 902
Treated NS/p<0,06 » 1811,25 1591,98 601,00 5270 692,25 1089,5 2492,75
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N = 21 14
CONTROLS TREATED UNTREATED
Fig. 3. Comparison o f  VEGF levels in CML treated and Fig. 4. Comparison o f  HGF levels in CML treated and
untreated patients and control group untreated patients and control group
Table 4. Correlation analysis (Spearmen 's Rho correlation test)
CML
HGF (pg/ml) VEGF (pg/ml)
WBC (G/L) rO.798; p<0.01 r=0.698; p<0.01
Blasts percentage in PB (%) p=0.728; p<0.01 No significance
Platelets (G/L) No significance t=0.484; p<0.05
LDH (IU/L) r=0.767; p<0.01 r=0.569; p<0.01
Splenomegaly (cm) 1=0.581 ;p<0.01 1=0.456: p<0.05
Our data indicate that CML is a disease highly associated 
with elevated plasma levels o f  VEGF and HGF, which cor­
roborates the thesis o f  its angiogenic dependency.
The most significant increase o f  VEGF level is found in pa­
tients in chronic phase o f CML as well as in the untreated 
group. Likewise, given its strong correlation with WBC,
LDH and splenomegaly (Table 4), VEGF plasma levels re- 
fleet the tumor burden in all phases o f CML.
It is notable that with the acceleration o f the disease to blast 
crisis, VEGF level does not increase but slightly decreases) 
which is contrary to some other results obtained by no« 
(16), and this could be due to the following reasons:
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• Platelets and megakaryocytes are one of foe main 
sources of VEGF release. To reduce this dependency 
we used plasma instead o f serum probes. Although this 
reinsurance, we found a significant correlation with 
platelets but no correlation was demonstrated with the 
blast percentage in PB;
• Having in mind that with foe progression o f CML foe 
main criterion is foe increase o f blasts over 25% and foe 
thrombocytopenia is a usual event, we can speculate 
that VEGF could not serve as a predictor for blast 
transformation;
• Insufficient number o f patients both in acceleration and 
blast transformation o f CML. Further study by our 
group is imminent in order to assess a significant 
number o f patients as well as the cellular VEGF protein 
expression in bone marrow' myeloid precursor cells and 
neovascularization.
The present study demonstrates that HGF could serve as a 
reliable marker reflecting the tumor burden as well as the 
activity and foe progression o f  foe disease. The high corre­
lation of HGF levels with WBC, blast percentage in PB, 
LDI I and splenomegaly suggests its possible clinical sig­
nificance as a method to follow-up patients with CML. In 
this respect, our results are in conformity with others (4,5), 
as the differences and correlations are more significant in 
our study, probably because o f the precise division o f  tire 
groups. As it is seen in Table 2 and Fig. 3, HGF level signif­
icantly increases in blast crisis o f  CML patients. It suggests 
its possible predictive value to blast transformation and, re­
spectively. it could serve as a prognostic factor.
One of the intriguing findings emerged from our study is 
that, with respect to both VEGF and HGF, there is evidence 
for foe existence of a threshold value to distinguish between 
healthy individuals and CML patients. Threshold values o f 
90pg/'m] and 1150pg/ml appear to exist for VEGF and 
IR if, respectively. With regard to clinical value, these re­
sults have demonstrated the potential usefulness o f VEGF 
and HGF as diagnostic and prognostic parameters.
Both VEGF and HGF levels decrease during the treatment 
of CML patients regardless o f foe phases of foe disease. So, 
it is rationale that an establishment o f such an angiogenic 
cytokine profile could be a reliable method o f assessing not 
only the angiogenic and disease activity but its suppression 
during foe treatment as well.
In summary, our present data lend support to previous stud­
ies suggesting that angiogenic factors play a functional role 
in CML. Obviously, VEGF and HGF have a great clinical 
significance winch must be confirmed with further investi­
gations, and including of more cases will allow a perfor­
mance of more accurate and extended analyses and conclu­
sions.
An extended prospective study is started by our group in 
order to analyze a sufficient number of patients with CML 
and other chronic MPD as well as to assess foe correlation 
of plasma levels o f VEGF and HGF to their cellular expres­
sions in bone marrow and neovascularization.
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